Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use

Nova Scotia Health Authority (NSHA)

Status: Withdrawn

Conditions: Adrenergic Pathology

Treatments: Drug: Administration of 123Iodine MIBG

Study type: Observational

Funder types: Other

Identifiers

NCT01912040

123Iodine MIBG

Details and patient eligibility

About

Assessing 123 Iodine MIBG produced locally for safety while being used in clinical practice to help in patient management decisions.

Full description

We will be assessing for adverse reactions of patients injected with locally manufactured 123 Iodine MIBG. With monitoring of blood pressure and heart rate following injection and any potential immediate side effects.

Sex: All

Ages: 1+ month old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with potential Adrenergic pathology

Exclusion criteria

• Pregnant or breast feeding females
• Hypersensitivity to MIBG

Trial design

0 participants in 1 patient group

Patients

Description:

Administration of 123Iodine MIBG to the patients referred .

Treatment:

Drug: Administration of 123Iodine MIBG